Home
 
to Order
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
































 

Modafinil in treatment of fatigue in multiple sclerosis, Results of an open-label study.

Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM.

Arbeitskreis fur klinische Forschung in der Neurorehabilitation Kurhausstr. 100 2222 Bad Pirawarth, Austria.
J Neurol 2002 Jul;249(8):983-7

Abstract

Background Modafinil is a unique wake-promoting agent that is chemically distinct from traditional stimulants. Results of a placebo-controlled study showed it to improve fatigue in multiple sclerosis (MS) at a dose of 200 mg daily, but not at a dose of 400 mg daily. Objective To establish the efficacy, safety and appropriate dose of modafinil in the treatment of fatigue and sleepiness in patients with multiple sclerosis. Method A total of 50 patients diagnosed with MS (mean age 40.4 10.3 years, 30 females/20 males; MS type: 36 relapsing remitting, 1 primary progressive, 13 secondary progressive; mean disability level 3.8 1.5 on the Kurtzke EDSS) and complaining of chronic fatigue were enrolled in a prospective 3-month, two-center, open-label study. Efficacy was evaluated with the Fatigue Severity Scale (FSS, score range 0-42), the Epworth Sleepiness Scale (ESS, score range 0-24) and by subjective patient appraisal of change of fatigue, quality of life and overall satisfaction with treatment. Adverse effects (AEs) were recorded throughout the study. Treatment was started with a single daily dose of 100 mg in all patients. In non-responders the dose was increased by 100 mg increments up to a maximum daily dose of 400 mg. Results Three patients discontinued modafinil because of AEs (nervousness, dizziness). Two patients (4 %) were treated with 50 mg, 25 (50 %) with 100 mg, 21 (42 %) with 200 mg and 2 (4 %) with 300 mg daily. No patient required 400 mg daily. Mean FSS scores were 30.3 8.5 at baseline and 25.4 3.7 at 3 months (p < 0.0001). Mean ESS scores were 9.7 3.9 at baseline and 4.9 2.9 at 3 months (p < 0.0001). Self-appraisal of change of fatigue showed clear improvement in 41 patients (87.2 %), some improvement in 4 (8.5 %) and no change in 2 (4.3 %). Overall clinical condition was clearly improved in 43 patients (91.5 %), somewhat improved in 1 patient (2.1 %), and unchanged in 3 patients (6.4 %). No patient reported worsening of overall clinical condition. Conclusions Treatment with modafinil significantly improves fatigue and sleepiness and is well tolerated by patients with MS. Unlike the higher dose regimen required in narcolepsy, a low-dose regimen of modafinil is effective in MS.

                                              |  Home  |  to Order  |

 1.   Modafinil  augmentation of antidepressant treatment
 2.   Modafinil  children with attention-deficit/hyperactivity disorder
 3.   Modafinil  in fibromyalgia treatment
 4.   Modafinil  efficacy in narcolepsy
 5.   Modafinil  narcolepsy: symptoms and management
 6.   Modafinil  successful treatment of hypersomnia & narcolepsy
 7.   Modafinil  drug of choice for narcolepsy
 8.   Modafinil  in the treatment of narcolepsy
 9.   Modafinil  effect on narcolepsy
10.  Modafinil  a narcolepsy study
11.  Modafinil  switching from narcolepsy drugs to modafinil
12.  Modafinil  and naps as counter measures in sleep deprivation
13.  Modafinil  as a treatment for excessive daytime sleepiness
14.  Modafinil  use in a sleep deprivation experiment
15.  Modafinil  excessive sleepiness in Parkinson's disease
16.  Modafinil  the unique properties of a new stimulant 
17.  Modafinil  for sustaining the alertness of helicopter pilots
18.  Modafinil  dosage and safety
19.  Modafinil  treatment of alcoholic organic brain syndrome
20.  Modafinil  effect on melatonin, cortisol, and growth hormone
21.  Modafinil  in obstructive sleep apnea-hypopnea syndrome
22.  Modafinil  vs dextroamphetamine in treatment of adult ADHD
23.  Modafinil  dopaminergic transmission mediates CNS stimulants
24.  Modafinil  for daytime sleepiness in sleep apnea
25.  Modafinil  treatment of residual excessive daytime sleepiness
26.  Modafinil  amplification of cortical serotonin release
27.  Modafinil  for the treatment of multiple sclerosis

| Order  |